Replies to post #388038 on NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

Many people, hedge funds and others, in my opinion, don’t understand that it’s looking like NWBO is creating a true class of long term GBM survivors, whereas in the past, most long term survivors getting SOC therapy were, by today’s standards, not suffering from GBM.

That is very interesting this could mean when setting the IDH patients aside we will see an even fatter OS than if they had not. The question I have when comparing with SOC, in present SOC so far IDH has not been excluded from what the WHO will probably call now GBM ex IDH... so how to compare DCVAX ex IDH with the history of SOC including IDH if NWBO does not have that IDH data to exclude from SOC?

thank for answering

[ATLnsider]

I agree flipper44…

[sukus]

Excellent post Flipper.

I bet RAs would love every efforts and preparations they had spent on this. That will also increase the level of quality on the data when announced.

[sentiment_stocks]

Yes, this makes sense to me as well.

My guess is that is perhaps one reason why, as I said a day or two ago, this trial ran on so long — because comparing conditional survival, by definition, requires a very mature set of data to reach statistical conclusions on longevity odds once impressive longevity already occurred in some patients.

I have found, over the many years of waiting on NWBO, that their actions make sense, in retrospect, when I'm looking back. And for me, not only do they make sense, but I have learned to fully trust their intents as honorable, especially, when looking back and in possession of the knowledge of what went on.

Quick examples, for instance, that come to mind would be the German issue that held up the Q. I'm not sure holding up the Q was a good idea, but I do remember a lot of us being quite concerned about what was behind the whole tax issue, only to find out that it really was a relatively minor issue. Another time that I recall was waiting on them raising funds using the Sawston property, where they intended, initially, to refinance the property and pull money out, only to find that they were selling the property to Huawei for a very decent profit, and had negotiated an extremely good long-term lease on the building they were intent on occupying. These are just a few examples... there are many for me. I'm sure others can think of episodes that lead them in the opposite direction, but this is my post, so I get to write how I see things in it. :)

[Umibe5690]

I totally agree with your post.

From my own research, it seems to me that NWBO’s trial has pioneered a truly remarkable immunological therapy for difficult to treat GBM.

From recent abstracts, it appears that what constitutes GBM has been refined and is rather better understood. The results of the NWBO trial will place an exclamation point on it.

As you know, GBM is now defined as pGBM and formerly classified GBM such as pro neural arises as a result of evolution from LGG. It is a sGBM. These tumors are predominantly IDHmt and indicate a more favorable survival outcome. Approximately 90~95% of GBM is IDHwt, however, and more difficult to treat. Hence, it appears reasonable to conclude that pGBM is composed of the molecular classifications of mesenchymal and classical. Proneural(and neural) are not included. Each has its own signature, i.e., NF-1, NF-kB mutations for MES and over-expression of EGRF resulting in a mutation of especially EGRFviii. The interplay of various genes such as TERT, PTEN, TPo53, etc. plus DNA methylation status have had up to now rather inconclusive results wrt to current therapies. Most of the abstracts that I have reviewed are surveys and reclassifications and analyses of the various stratifications of GBM(M, IDH, methylation, etc.) and various therapeutic approaches. Interestingly, not one of the many abstracts/commentaries have mentioned NWBO/DCVAX although TTF has sparingly been mentioned in passing. All of this will rapidly change with the announcement of TLD.

From the foregoing, NWBO is pioneering a new paradigm in treating an intractable and terminal disease. A lot of analyses have issued in recent years and I am betting that the rigorous and far reaching analysis of all the data that has been accumulated over the past 14 years in NWBO’s trial will explain hopefully to a large extent what I believe will be truly remarkable results. I can well understand the time it has thus far taken, taking into consideration all of the rigorous and detailed commentaries that have come forth in recent years.

I can well understand Dr. Ashkan’s hope that the vaccine should be available to everyone who has been diagnosed with pGBM(=GBM). We know from previous clinical trials that the vaccine has been seen to work especially well in MES, and, I think, even better with MGMT methylation. It also appears to have some effect on classical. For example, if I recall correctly, Brad Silver had classical/methylated. Proneural, which is predominantly IDHmt, is not classified any longer as GBM evolving from a LGG. In any event, proneural makes up a rather de minimis percentage of overall GBM. I believe the odds are that DCVAX works for all pGBM and for some stratifications better than others. JMHO.